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Abstract 
Background: DNA methylation is commonly linked with the silencing of the gene expression for many tumor 
suppressor genes. As such, determining DNA methylation patterns should aid, in times to come, in the diagnosis 
and personal treatment for various types of cancers. Here, we analyzed the methylation pattern from five colorectal 
cancer patients from the Amazon state in Brazil for four tumor suppressor genes, viz.: DAPK, CDH1, CDKN2A, and TIMP2 
by employing a polymerase chain reaction (PCR) specific to methylation. Efforts in the study of colorectal cancer are 
fundamental as it is the third most of highest incidence in the world.
Results: Tumor biopsies were methylated in 1/5 (20 %), 2/5 (40 %), 4/5 (80 %), and 4/5 (80 %) for CDH1, CDKN2A, 
DAPK, and TIMP2 genes, respectively. The margin biopsies were methylated in 3/7 (43 %), 2/7 (28 %), 7/7 (100 %), and 
6/7 (86 %) for CDH1, CDKN2A, DAPK, and TIMP2, respectively.
Conclusions: Our findings showed DAPK and TIMP2 to be methylated in most samples from both tumor tissues and 
adjacent non‑neoplastic margins; thus presenting distinct methylation patterns. This emphasizes the importance of 
better understanding of the relation of these patterns with cancer in the context of different populations.
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Background
Colorectal cancer (CRC) comprehends tumors that affect 
the colon and rectum; it is the third type of cancer with 
the highest incidence in the world [1]. According to the 
2014 estimates for Brazil, about 576,000 new cases of 
cancer were expected [2] of which 15,070 of those being 
for CRC in men and 17,530 for women. In particular, for 
the Amazon state (Brazil), a rate of 4.65 cases per 100,000 
inhabitants [2] was estimated. The standard treatment for 
localized colorectal cancer involves surgical resection by 
open surgery of the primary tumor and regional lymph 
nodes. It has been shown that excessive consumption of 
red meat, alcoholism, body and abdominal fat, smoking, 
family history of CRC, genetic susceptibility to the devel-
opment of chronic intestine disease, and age are all posi-
tively correlated to CRC [3, 4]. Nevertheless, about 90 % 
of CRC occurs sporadically and without family history or 
genetic predisposition; i.e., less than 10 % of the cases are 
believed to be linked to one’s genetics [5].
The study of epigenetics alterations has gained 
increasing attention; it comprises investigating how 
external or environmental factors affect the control of 
gene expression by turning genes “on” or “off” [6]. An 
example of a key epigenetic event is the methylation that 
occurs in small regions of DNA called CpG island which 
are located in the promoter region of genes [7]. Meth-
ylation defines the process of adding a methyl (CH3–) 
group in the promoter cytosine bases at the 5′ position 
to form 5-methylcytosine (5-MC). DNA methylation 
is usually linked with the silencing of gene expression 
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for many tumor suppressor genes, such as, CDH1 [8], 
CDKN2A [9], TIMP2 [10], and DAPK [11]. The CDH1 
gene expresses E-cadherin which is a transmembrane 
protein contained between epithelial cells and repre-
sents one of the main proteins involved in cell adhe-
sion [12]. The loss of adhesion mediated by E-cadherin 
appears to have a fundamental importance in neoplastic 
processes. A down regulation of this gene is correlated 
with a decrease in the efficiency of cellular adhesion 
and therefore facilitating cellular motility; this in turn 
facilitates cancer cells for invading surrounding tissues 
[8]. Another gene strongly correlated to cancer is the 
CDKN2A; one of its products is the p16, a regulatory 
protein that inhibits the progression of cells through the 
G1 phase of the cell cycle [11]. Inactivation of p16 can 
cause abnormal cells and uncontrolled cell growth [13]. 
The TIMP2, for tissue inhibitor of metalloproteinases 
2, is known to antagonize the activity of matrix metal-
loproteinases and suppress tumor growth, angiogenesis, 
invasion, and metastasis [14]; the mechanism of inhibi-
tion of this gene’s expression remains unknown. Finally, 
DAPK (for death-associated protein kinase) participates 
in several functions in the cell, among them, playing 
a key role in the reorganization of the cytoskeleton in 
cytokine stimulation and induction of apoptosis [11]. 
Understanding DAPK’s role in transcriptional regulation 
may lead to the discovery of novel therapeutics to com-
bat cancer and inflammation associated diseases.
According to literature, abnormal methylation pat-
terns of these genes is an indicative of cancer [15–18]. 
Studies have reported such alterations, for example, in 
the mucosa of colorectal tumor and suggested these 
genes as cancer markers [19, 20]. In another work, the 
hypermethylation of DAPK and CDKN2A in the normal 
colonic mucosa of patients with CRC was evaluated by 
the methylight assay and the results showed their lev-
els of methylation to be relatively low [mean percentage 
of a methylated reference (PMR) <1] [20]. In the same 
work, the authors correlated patients with high lev-
els of methylation of INK4A and DAPK with advanced 
age (p  <  0.1), supporting the hypothesis that age is one 
of the risk factors for this pathology. Finally, a panel of 
methylation markers for CRC diagnosis comprising 
CDKN2A, MGMT, MLH1, and SFRP was proposed [21].
Even though epigenetic markers are being increas-
ingly applied in the screening for colorectal neoplasia’s 
samples, further investigations, especially in different 
populations, is fundamental for a proper understanding 
of the applicability of these markers to the clinical prac-
tice. In the present study, we evaluated the methylation 
of the CDH1, DAPK, CDKN2A, and TIMP2 genes in five 
colorectal cancer patients from Manaus, the capital of 
the Amazon state in Brazil. Although the Amazon region 
presents a predominance of Indians, with approximately 
342,800 indigenous people [22], this study included only 
patients recognized as having brown or white skin. This is 
the first study of this type performed in the population of 
the Amazon region.
Results
Table  1 shows the clinical characteristics of the five 
patients included in this study; we note that 20  % (1/5) 
of the tumors were located in colon and 80  % (4/5) in 
the rectum. The median age of the patients was 62 years. 
All the patients had resection margins free of neoplasia 
according to a histopathological exam. These results were 
compared to the methylation status obtained here. All of 
the tumor-node-metastasis (TMN) stages analyzed here 
had one or more genes methylated. Table  2 shows the 
gene methylation status for the CDH1, CDKN2A, DAPK, 
and TIMP2 genes.
Tumor biopsies were methylated in 1/5 (20  %), 
2/5 (40  %), 4/5 (80  %), and 4/5 (80  %) for the CDH1, 
CDKN2A, DAPK, and TIMP2 genes, respectively. 
The margin biopsies were methylated in 3/7 (43  %), 
2/7 (28  %), 7/7 (100  %), and 6/7 (86  %) for the CDH1, 
CDKN2A, DAPK, and TIMP2 genes, respectively. In all, 
64 % (18/28) of the resection margins and 55 % (11/20) of 
tumor tissue were methylated for the four genes.
Patient 4 had the tumor biopsy (4T) and margins (4PM 
and 4DM) methylated for all, CDH1, CDKN2A, DAPK, 
and TIMP2, except for 4DM not being methylated for 
CDH1. The tumor tissue of patient 8 (8T) and the respec-
tive adjacent margin (8DM) were not methylated for 
Table 1 Patients’ clinical characteristics
M male, F female, TMN tumor-node-metastasis
Patients no/sample Cancer type Gender Age (years) Skin color Stage (TMN)
4 Rectal adenocarcinoma M 65 Brown T3N0M0
7 Colon adenocarcinoma M 40 Brown T3N0M0
8 Rectal adenocarcinoma F 74 Brown T4N2M0
1 Rectal adenocarcinoma M 61 Brown T3N0M0
9 Rectal adenocarcinoma M 62 White T3N1M0
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CDH1 and CDKN2A; yet, DAPK and TIMP2 were both 
methylated for 8T and 8DM. These results were simi-
lar to those from patient 9DM; other sections from this 
patient, in our hands, were unable to have their genes 
amplified by PCR. Patient 1 showed 1T to be methylated 
for CDKN2A and DAPK and not for CDH1 and TIMP2. 
DAPK showed to be methylated for 1DM. 7T was not 
methylated for 7DM but was methylated for both DAPK 
and CDH1 and thus showing a different methylation pat-
tern. Amplification of CDH1 gene (1T, 6T, and 9DM sam-
ples) and TIMP2 (sample 1DM) were unsuccessful and 
methylation could not be analyzed.
Discussions
The DNA methylation leads to an altered gene expres-
sion resulting in changes in the control of cell prolifera-
tion and therefore being recognized as a major epigenetic 
modification in human genes [19]. There is increasing 
evidence that an aberrant methylation pattern is actively 
involved in early carcinogenesis [7]. In colorectal cancer, 
both hyper- and hypomethylation have been observed 
across different stages of progression. Here, we evalu-
ated the prevalence of hypermethylation in the CDH1, 
CDKN2A, DAPK, and TIMP2 suppressor tumors genes 
of colorectal tumors tissue and their non-neoplastic 
adjacent margin using methylation specific PCR (MSP), 
which is a highly sensitive and specific technique [23].
Subjects having either brown or white skin were eligi-
ble for participating in this study. We note that the brown 
classification decurrently from the so called caboclos, 
descendants of Indians and Europeans—mostly English, 
French, and Spanish, that are commonly found in the 
northern part of Brazil [24]. It is the first time a study 
addressing the methylation pattern in colorectal can-
cer patients from the Amazon is performed. Our results 
show that each individual presented a distinct panel of 
methylated genes. In general, the methylated tumor tis-
sues had their respective margin methylated. Likewise, 
genes, not methylated in tumor tissues were not meth-
ylated in their adjacent margin. Yet, patient 7 showed 
an opposing result by not presenting methylation on 
the tumor for genes DAPK and CDH1; these genes were 
methylated only in the respective adjacent margins (7PM 
and 7DM). We hypothesize that this may have happened 
considering that methylation is a reversible process [25] 
and, in this way, the gene could have been previously 
methylated in the tumor but metabolic factors reversed 
it. Another probable explanation is that tumor cells have 
a great heterogeneity [26] and, therefore, the examined 
area was not methylated.
The literature provides several studies that compare 
the methylation status of histologically normal mucosa 
with the neoplastic tissues. While some show no cor-
relation between the methylation with the pathology, 
many studies, from around the world, were able cor-
relate methylation of the tumor region and the corre-
sponding adjacent margin [27–30]. Li et al. reported that 
2.4 and 57.4  % of the samples were methylated in their 
tumor and adjacent tissue and that no methylation was 
detected in all the control tissue. A meta-analysis study 
revealed the frequency of the CDH1 promoter methyla-
tion in CRC tissues to be higher than those in control tis-
sues (OR = 2.61, 95 % CI = 1:24–5:50, p = 0.012) [31]. 
When the ethnicity factor was considered, the CDH1 
promoter methylation showed to be closely linked to the 
pathogenesis of CRC among Asians and Africans, but 
not among Caucasians. Our results show that the CDH1 
promoter methylation in tumor tissue was lower than in 
the adjacent margins. CDH1 gene promoter methylation 
may lead to aberrant expression of E-cadherin [32]. The 
loss of adhesion mediated by E-cadherin appears to have 
a fundamental importance during the neoplastic pro-
cesses, which allows cells having a controlled stop normal 
growth signaling, resulting in the loss of differentiation 
and increase in cell proliferation associated with the inva-
sive behavior [8].
Xing et  al. showed that hypermethylation of the 
CDKN2A gene correlated with a poor prognosis for CRC 
in European and Asian patients [28], but not for patients 
from other locations. In this regard, Xing et al., highlights 
the importance of more studies in different geographi-
cal locations to determine and clarify whether such 
Table 2 Methylation status of  CDH1, CDKN2A, DAPK 
and TIMP2 genes
NA not amplified, U unmethylated, M methylated, T tumor, PM proximal margin 
(2 cm), DM distal margin (5 cm)
Patient no/sample Methylation
CDH1 CDKN2A DAPK TIMP2
4 T M M M M
4 PM M M M M
4 DM U M M M
7 T U U U M
7 PM M U M M
7 DM M U M M
8 T U U M M
8 DM U U M M
1 T NA M M NA
1 DM U U M NA
9 T U U M M
9 DM NA U M M
Methylation tumor (%) 1/5 (20 %) 2/5 (40 %) 4/5 (80 %) 4/5 (80 %)
Methylation adjacent 
margin (%)
3/7 (43 %) 2/7 (28 %) 7/7 (100 %) 6/7 (86 %)
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suppressor genes serve as a prognostic factor for patients 
with CRC. In our study, the percentage of methylation for 
CDKN2A was 2/5 (40 %) for tumors tissue and 2/7 (28 %) 
for adjacent margins. Kuan et  al. showed that advanced 
stage CRC patients presenting CDKN2A/p16 methyla-
tion were associated with higher risk of CRC recurrence 
as compared to those with tumor tissues that were not 
methylated [30].
In the literature, the methylation status of TIMP2 and 
DAPK is far from a global picture. Here, 80  % (4/5) of 
tumor samples and 86  % (6/7) of the adjacent margins, 
respectively, were methylated for TIMP2. However, in a 
histologically exam all margins were diagnosed as being 
free of tumor. For DAPK, 80  % of tumor samples and 
100  % of the margins samples were methylated. Since 
DAPK is methylated, its anti-metastatic function is pre-
sumed to be lost [33]. Therefore, this work is aligned with 
the thesis that DAPK methylation poses as an important 
marker for the invasion, metastasis, and apoptotic pro-
cesses in colorectal neoplasias and thus, ultimately, a 
potential marker for diagnosis and prognosis.
Even though epigenetic markers are being increasingly 
applied in the screening for colorectal neoplasia samples, 
there is still need for further investigations, especially in 
different populations, such as in Manaus. Although the 
number of patients in this report is small to draw solid 
conclusions on the importance of these markers in the 
context of Manaus population, the TIMP2 and DAPK 
were methylated on almost all tumors. Furthermore, our 
results showed a correlation with previous works, thus, 
supporting our claims.
Conclusion
Taken together, our results disclose methylation pat-
terns for the CDH1, CDKN2A, DAPK, and TIMP2 genes 
on tumors and their respective margins. Although this 
report was limited to five patients, our results can serve 
as building blocks for future studies comprising meta-
analysis of these genes and thus ultimately contributing 
to generating models with more statistical power. Such 
large-scale studies should consider establishing panels 
tailored towards specific population. Our observations 
pinpointed the heterogeneity of specific molecular abnor-
malities in each patient; most noticeably, the TIMP2 and 
DAPK genes were methylated in almost all samples of 
tumor and their adjacent margins. Yet, adjacent margins 
were diagnosed as disease-free according to the histo-
pathological assessment. These facts make evident that 
a better understanding of these methylation patterns are 
fundamental, in time to come, to aid in developing more 




This study was approved by the Ethics Committee of 
the Federal University of Amazonas (UFAM: MEMO, 
No. 27598614.1.0000.5020, CAAE). The samples were 
collected at the Oncology Control Center Foundation 
of Amazonas State (FCECON). After signing informed 
consent, five patients diagnosed with adenocarcinoma 
were evaluated. We obtained biopsies of the tumor (T), 
distal margin (DM), and proximal margin (PM) from two 
patients (Fig. 1) and only T and DM from the remaining 
three. Taken together, there were 12 biopsies. These sam-
ples were stored at −80 °C. The study includes patients of 
both genders, all aging between 18 and 80 years and pre-
senting CRC diagnosed by colonoscopy and biopsy.
DNA extraction
The tissues were pulverized with liquid nitrogen and the 
DNAs were extracted from each sample using the kit 
InnuPrep Forensic (Biometra, Germany) according man-
ufacturer’s recommendations. The DNAs were quantified 
using NanoDrop 2000 (Thermo, USA).
Sodium bisulfite modification
Two micrograms of DNA were used to a final volume 
of 20  µL in sodium bisulfite modification according the 
recommendations of the EZ DNA Methylation-Lightning 
kit manufacturer (Synapse, Germany). Briefly, 130 µL of 
lightning conversion reagent were added to 20  µL con-
taining DNA, vortexed and incubated at thermocycler 
(Mastercycler Gradient, Eppendorff) under the con-
ditions: 98  °C for 8  min, 54  °C for 60  min and 4  °C for 
10 min to finish. After transferring the sample to the col-
umn, we added 600  µL of M-binding buffer, mixed and 
centrifuged for 30  s at 10,000×g. The supernatant was 
Fig. 1 Colorectal cancer tissue obtained after surgery. The tissue was 
separated into tumor, proximal margin (2 cm), distal margin (5 cm)
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discarded, 100 µL of M-washing buffer were added, cen-
trifuged again at 10,000×g for 30 s, and added to 200 µL 
of buffer l-desulphonation. The solution was incubated 
at room temperature for 20 min and then centrifuged at 
10,000×g for 30 s. Another washing step was performed 
with 200 µL of M-washing buffer and then centrifuged at 
10,000×g for 30  s. The modified DNA was eluted from 
the column by adding 13 µL of M-elution buffer.
Methylation‑specific PCR (MSP)
DNA from the biopsies was subjected to bisulfite treat-
ment and later was amplified by MSP, using primers 
specific to distinguish methylated from unmethylated 
DNA in bisulfite-modified DNA, taking advantage of the 
sequence differences resulting from bisulfite modifica-
tion. The treatment with bisulfite results in conversion of 
unmethylated cytosines to uracil and leaves methylated 
cytosine intact. To detect these changes, specific primers 
were used (Table 3), as described previously [34–37].
For PCR analysis, 1 µL of bisulfite modified DNA in a 
final volume of 12.5 µL of reaction mixture was used con-
taining 1× PCR buffer, MgCl2 1.25 mM, 0.2 mM dNTPs, 
0.4 M of each primer, 0.3U Taq polymerase (5U/µL). The 
reactions methylated and unmethylated were performed 
in a mastercycler thermocycler (Eppendorff) and the 
parameters were: 96  °C for 1  min followed by 35 cycles 
of 94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min and 
final extension step of 72 °C for 7 min. The PCR product 
(10 µL) was directly loaded onto 10 % polyacrylamide gel 
stained with silver. Negative controls used in PCR were 
reaction mixture without DNA.
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